Lindahl law firm has advised Sprint Bioscience AB (publ) in connection with its rights issue of new shares and warrants (units). The proceeds from the rights issue will be used primarily to expand sales efforts as well as to increase the number of projects that the company assesses that it can develop through the preclinical phase as far as required for a subsequent licensing. A prospectus regarding the rights issue was announced on 14 February 2018.
Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry and has the goal to develop drug candidates for the global pharmaceutical market within the field of oncology in a more time- and resource-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint Bioscience share is listed on Nasdaq First North Premier and traded under the name SPRINT.
Lindahl has assisted Sprint Bioscience in the transaction with a team headed by Maria Arnoldsson (Capital Markets and public M&A), Anders Burén (Life Science) and Per Hedman (Life Science), together with Anton Knifström and Oscar Lunde (Capital Markets and public M&A) and Anna Romell Stenmark and Isabella Rosman (Tax).
